>
Switch to:

Biomarin Pharmaceutical Price-to-Free-Cash-Flow

: 93.92 (As of Today)
View and export this data going back to 1999. Start your Free Trial

As of today (2021-10-15), Biomarin Pharmaceutical's share price is $75.89. Biomarin Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $0.81. Hence, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow Ratio for today is 93.92.

The historical rank and industry rank for Biomarin Pharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:

NAS:BMRN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 92.86   Med: 103.49   Max: 168.58
Current: 93.92

92.86
168.58

During the past 13 years, Biomarin Pharmaceutical's highest Price-to-Free-Cash-Flow Ratio was 168.58. The lowest was 92.86. And the median was 103.49.

NAS:BMRN's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 30 Companies
in the Biotechnology industry.

( Industry Median: 26.42 vs. NAS:BMRN: 93.92 )

Biomarin Pharmaceutical's Free Cash Flow per Share for the three months ended in Jun. 2021 was $0.31. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.81.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 38.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -2.40% per year.

During the past 13 years, Biomarin Pharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 71.50% per year. The lowest was -131.90% per year. And the median was 3.70% per year.


Biomarin Pharmaceutical Price-to-Free-Cash-Flow Historical Data

The historical data trend for Biomarin Pharmaceutical's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 160.32 103.27

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Price-to-Free-Cash-Flow falls into.



Biomarin Pharmaceutical Price-to-Free-Cash-Flow Calculation

Biomarin Pharmaceutical's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=75.89/0.808
=93.92

Biomarin Pharmaceutical's Share Price of today is $75.89.
Biomarin Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Biomarin Pharmaceutical  (NAS:BMRN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Biomarin Pharmaceutical Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)